Home » Newsletters » BioWorld Science

BioWorld Science

March 9, 2011

View Archived Issues

Microbicide vaginal gel containing C2F5/C4E10/C2G12 MAbs for HIV-1 is safe in phase I trial

Renovo discloses exploratory analysis data on Juvista and announces restructuring

Gemtuzumab ozogamicin improves survival of patients with AML and favorable cytogenetics

Lilly submits application seeking additional indication for Zyprexa in Japan

European orphan drug status for Talecris' human plasmin in acute peripheral arterial occlusion

Multiple-antigen MVA/DNA HIV vaccine regimen is safe and immunogenic in phase I trial

EMA accepts Insmed's pediatric investigation plan for Arikace

Vanda Pharma's tasimelteon receives European orphan drug status in N24HSWD

FDA accepts for review dapagliflozin NDA for type 2 diabetes

Inovio begins phase II VGX-3100 vaccine program for cervical dysplasia caused by HPV

New lysophospholipid S1P1 receptor agonists reported by Bristol-Myers Squibb

Amgen acquires BioVex

Primary endpoint met in phase II trial of inhaled bimosiamose in COPD

Amira Pharma describes salts of a prostanoid DP2 receptor antagonist

Downregulated FGFR-3 expression predicts poor outcome of pancreatic islet cell tumors

Concert Pharma prepares new deuterated PGI2 receptor agonists

GSK patents new activators of Toll-like receptor 7 and/or 8

Novel inhibitors of HCV RNA replication designed at Tibotec

New topiramate label warns for risk of oral clefts in newborns

AstraZeneca and Galderma to develop dermatological therapies

Novartis Diagnostics to market Grifols' immunohematology diagnostics in U.S.

Kaletra label changed due to health risks in premature babies

FDA committee recommends approval of QAB-149 to treat airflow obstruction in COPD

Amsterdam Molecular Therapeutics receives grant to develop AMT-080 for Duchenne's muscular dystrophy

Phosphorylated forkhead box protein O1 has prognostic value in pancreatic ductal adenocarcinoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Neutrophils put the brakes on fat loss
BioWorld Science
Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...